Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104,... Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0225 | 2.34375 | 0.96 | 1.09 | 0.95 | 60863 | 0.98880318 | CS |
| 4 | -0.0875 | -8.17757009346 | 1.07 | 1.23 | 0.9 | 49734 | 1.04214605 | CS |
| 12 | -0.9875 | -50.1269035533 | 1.97 | 2 | 0.9 | 43877 | 1.34054669 | CS |
| 26 | -0.5375 | -35.3618421053 | 1.52 | 2.1 | 0.8936 | 127510 | 1.34283356 | CS |
| 52 | 0.0757 | 8.34803705337 | 0.9068 | 3.15 | 0.78 | 143509 | 1.70593764 | CS |
| 156 | -4.2275 | -81.1420345489 | 5.21 | 5.62 | 0.63 | 111291 | 1.49636428 | CS |
| 260 | -4.2275 | -81.1420345489 | 5.21 | 5.62 | 0.63 | 111291 | 1.49636428 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。